The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.

Party season approaches; but first, conferences.

GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.

Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.

Kura will see more combo data, while a new contender from Sumitomo emerges.

An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.

The group goes after a KRAS-related target on which Boehringer recently gave up.

The company reckons it’s got what it takes to hit the right member of the FGFR family.

The Hutchmed-originated savolitinib moves towards its first US approval.

Meanwhile, Tecvayli stalls, but J&J still hopes for growth.